thebiostories

🌏 Available in: English | 한국어 Frank Macfarlane Burnet: The Nobel Prize Winner Who Shaped Modern Immunology  Quick Poll Who do you think is Australia's most influential scientist? Thanks for voting! Results reflect votes from your browser. If you asked most people to name a famous Australian scientist, you'd probably hear Howard Florey, the man behind penicillin's development into a usable drug. Maybe Peter Doherty, or more recently, Elizabeth Blackburn. Far fewer people would say Frank Macfarlane Burnet — and that's a genuine oversight, because his ideas quietly underpin almost everything modern medicine understands about the immune system. Burnet never discovered a single blockbuster drug. He did something arguably more foundational: he figured out how the immune system tells the difference between "you" and "not you." Understanding that distinction is the reason organ transplants can wor...

🌏 Available in: English | 한국어 An Australian Discovery Reveals a Dysregulated Immune Pathway in Acute Rheumatic Fever How a Common Infection Can Lead to Lifelong Heart Disease Every year, hundreds of millions of people are infected with Group A Streptococcus (GAS). For almost everyone, it is a routine infection that disappears within days. But for a small number of people, the real disease begins only after the bacteria are gone. Years later, their immune system continues attacking the heart, eventually causing permanent valve damage known as rheumatic heart disease. Although molecular mimicry has long been considered the leading explanation, it could not fully explain why inflammation persists after the infection has been eliminated. Why does this happen? A landmark study published in Circulation in 2018 provided an important piece of the puzzle by identifying an immune pathway that helps explain why inflammation can persist long after the infection has been cleared. Molecular Mi...

🌏 Available in: English | 한국어 The Mice Behind Modern Medicine: The Hidden Heroes Behind Medical Breakthroughs Behind almost every breakthrough medicine is a discovery. Behind many of those discoveries is a mouse. When people hear about a new cancer drug or a life-saving vaccine, they usually imagine scientists working in laboratories or doctors treating patients. Few realise that many of those breakthroughs were made possible by laboratory mice, long before the first human clinical trial ever began. Little but Mighty Mice Why mice? Not because they are small. Not because they are inexpensive. But because they allow scientists to ask biological questions that simply cannot be answered in humans. They share much of our genetic blueprint, develop many of the same diseases, and can be genetically engineered with remarkable precision. Together, these features have made mice indispensable to modern biomedical research. Genetically Engineered Mice Transgenic mice are animals wh...

🌏 Available in: English | 한국어 How Was Venetoclax Developed? The Australian Story Behind a Breakthrough Cancer Therapy Every breakthrough medicine begins with a question. For Venetoclax, that question was not simply: How can we kill cancer cells? The deeper question was: Why do some cancer cells refuse to die? Today, Venetoclax is recognized as one of the most important targeted therapies for blood cancers, including chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML). Unlike traditional chemotherapy, Venetoclax works by targeting a specific survival mechanism used by cancer cells. It blocks a protein called BCL-2 , allowing cancer cells to restart a natural process called apoptosis , or programmed cell death. However, the story of Venetoclax did not begin with a drug. It began decades earlier with a fundamental discovery made in a Melbourne research laboratory. The Melbourne Discovery That Changed Cancer Biology The story begins a...

🌏 Available in: English | 한국어  실험실에서 이사회까지: WEHI의 스타트업 생태계 Science, Nature, Cell에 실린 새로운 생의학 발견은 치료법이 없어 고통받는 환자들에게 새로운 희망의 시작이 될 수 있습니다. 그러나 논문은 그 자체로는 아무도 치료하지 못합니다. 실험실에서 얻은 놀라운 결과가 병원에서 처방되는 약으로 이어지기까지는 수많은 사람들의 노력이 필요합니다. 그 사이 어딘가에서 누군가는 연구비를 마련하고, 회사를 세우며, 아직 시장조차 존재하지 않는 아이디어와 순수한 과학적 호기심에서 탄생한 발견에 투자할 가치가 있다는 사실을 투자자들에게 끊임없이 설득해야 합니다.   WEHI에서는 이제 그 '어딘가'에 이름과 펀드, 그리고 하나둘씩 늘어나는 스타트업 목록이 생겼습니다. 생물학적 발견과 치료제 개발 사이의 파트너쉽 베네토클락스는 무엇이 가능한지 보여주는 하나의 성공 사례입니다: BCL-2라는 단백질에 대한 1988년의 실험실 관찰이 결국 전 세계 수만 명의 환자가 사용하는 항암제가 되었고, 수억 달러의 로열티를 WEHI에 되돌려줬습니다. 하지만 이 결과가 나오기까지 거의 30년이 걸렸고, 제넨텍과 애브비 같은 다국적 제약회사가 WEHI의 초기 연구를 이어받아 끝까지 끌고 가야 했습니다. 모든 발견이 그런 파트너를 만나는 건 아닙니다. 점점 더 많은 WEHI의 획기적인 발견들이 이제 다른 경로를 택하고 있습니다: 기존 제약 대기업에 아이디어를 라이선싱하는 대신, WEHI는 연구자들이 그 발견을 하나의 과학적 통찰을 중심으로 처음부터 새로 세워진 독자적인 회사로 스핀아웃하도록 돕고 있습니다. 66ten — WEHI의 야심찬 벤처펀드 이 변화에는 이름이 있습니다: 그 변화를 이끄는 건 바로 66ten — WEHI의 첫 전략 투자 펀드이자, 호주 의학연구소 안에 기반을 둔 펀드 중 가장 큰 규모입니다. 6,600만 달러 규모로, 2033년까지 전액을 투입하는 것을 목표로 하는...